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Objectives: to analyze factors that might indicate familial predisposition for 
ovarian cancer in patients diagnosed with this disease. 
Methods: in a prospective single center cohort study at the Institute of Cancer 
of the State of São Paulo (ICESP), 51 women diagnosed with ovarian cancer were 
included. Familial predisposition for ovarian cancer was defined as having a 
higher than 10% chance of having a BRCA1/2 mutation according to the Man-
chester scoring system, a validated method to assess the likelihood of mutation 
detection. Each patient was interviewed with a standardized questionnaire on 
established risk factors for ovarian cancer and other factors that might influ-
ence the risk to develop ovarian cancer. Logistic regression analyses were per-
formed to estimate the impact of the evaluated factors on the likelihood of mu-
tation detection, by calculating odds ratios and 95% confidence intervals. 
Results: seventeen out of 51 patients had a family history of breast and/or ovar-
ian cancer, four patients had a history of breast or endometrial cancer, 11 were 
diagnosed before the age of 50, and 12 presented a risk of familial predisposi-
tion to ovarian cancer higher than 10%. Patients with comorbidities, such as hy-
pertension, diabetes, hormonal disorders, dyslipidemia and psychiatric condi-
tions, presented a lower chance of having a familial predisposition for ovarian 
cancer (OR: 0.22; 95% CI: 0.06-0.88; p=0.03). 
Conclusion: in this study, having comorbidities was associated with a lower risk 
of having a familial predisposition for ovarian cancer. Other factors associated 
with the risk of ovarian cancer did not have an impact on this predisposition.
Keywords: ovarian neoplasms, hereditary breast and ovarian cancer syndrome, 
neoplastic syndromes, hereditary, risk factors.
introduction
Ovarian cancer is one of the most common gynecologi-
cal malignancies. In Brazil, 6,190 new cases were estimat-
ed for the year 2012, 28% of which, in the state of São 
Paulo.1 It is the eighth most common cancer2 and the 
sixth cancer-related cause of death3 among women in the 
state of São Paulo. Most cases are diagnosed at advanced 
stages, associated with a 5-year survival rate as low as 32%.4 
The delay on diagnosis occurs mainly due to lack of symp-
toms in early stages and early spreading of the disease.
Approximately 5 to 10% of all ovarian cancer cases 
have a genetic predisposition, most often related to a 
BRCA1 or BRCA2 gene mutation. Women who carry a mu-
tation have a significantly increased risk of developing 
the disease. The cumulative incidence of ovarian cancer 
at age 70 is estimated to be 40% (95% CI: 35-46%) in BRCA1 
mutation carriers and 18% (95% CI: 13-23%) in BRCA2 mu-
tation carriers.5 The estimate was based on a meta-analy-
sis of ten studies addressing BRCA1/2 penetrance. Great 
heterogeneity was observed among reported risks on the 
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studies, as risks vary depending on the population stud-
ied and ascertainment method. The ten studies included 
in the meta-analysis were performed in the United States, 
England, Australia and Italy.
There are no studies addressing specifically family 
predisposition or BRCA1/2 mutations in ovarian cancer 
patients in Brazil and, despite the importance of this dis-
ease for public health, the country lacks precise national 
epidemiologic data on it. Hence the prevalence of BRCA1/2 
mutations in the Brazilian population and the risk of 
these women developing ovarian cancer have not yet been 
well established.
Since the availability of genetic testing is very limited 
in Brazil, a preliminary step would be to characterize fam-
ily history and predisposing factors associated with high 
risk of ovarian cancer in the Brazilian women. It would be 
important to have more information on ovarian cancer pa-
tients, analyzing possible factors that might indicate a ge-
netic predisposition to the disease, as well as other factors 
that could impact ovarian cancer risks. With that informa-
tion, we would be able to estimate cancer risks more pre-
cisely, providing women with more individualized coun-
seling. These women could be referred to a geneticist, who 
could provide family counseling, proposing screening and 
preventive measures for unaffected family members.6 Such 
personalized care is very important considering the life 
changing decisions that women at high risk for breast and 
ovarian cancer must make regarding cancer prevention.7-9
This study aimed at characterizing women with ovar-
ian cancer in Brazil. Another aim was to test the associa-
tion of predisposing factors to ovari an cancer with the 
risk of having a hereditary predisposition for the disease. 
Identifying factors associated with a higher risk of famil-
ial predisposition for cancer would be of great value for 
physicians who treat ovarian cancer patients with limit-
ed access to genetic testing.
Methods
Patients
In a prospective, single-center cohort study, patients diag-
nosed with ovarian cancer that were undergoing either 
treatment or follow-up at the Institute of Cancer of São 
Paulo (ICESP) were invited to participate in this study. In-
clusion criteria were: pathology report confirming epithe-
lial ovarian cancer, age older than 18 and diagnosis of pri-
mary tumor between 2009 and 2012. Exclusion criteria 
were: borderline tumors (except cases with invasive areas), 
benign lesions, cases of metastatic tumors from other pri-
mary sites and tumors diagnosed before 2009. This study 
was approved by the Institutional Ethics Committee and, 
after explanation of its purposes, patients who agreed on 
participating signed an informed consent form.
Questionnaire
A questionnaire covering demographic characteristics, 
anthropometric measures, hormonal exposure during 
life, life habits, tumor characteristics, and family history 
of cancer was developed for this study (Table 1). A pilot 
study was performed including four patients in order to 
improve both the questionnaire and the inquiry meth-
ods. After receiving a detailed explanation of the study, 
each patient answered all questions made by the inter-
viewer, who filled in the questionnaires. All patients were 
interviewed by the same person. The interviews were all 
performed in a private room and patients were guaran-
teed the confidentiality of their information. From fam-
ily history information, a pedigree was drawn for each 
patient included in this study. All information obtained 
was entered into an SPSS version 20.0 database for fur-
ther analysis.
Outcomes
Based on information gathered regarding family history 
and age of onset of tumors in the patients themselves 
and/or family members, the likelihood of having a famil-
ial predisposition for ovarian cancer, which might be as-
sociated with the presence of a genetic mutation, was cal-
culated for each patient using the Manchester scoring 
system,10 which is based on the patient’s personal and 
family history of cancer. This system is relatively simple 
compared to computer models used to access mutation 
detection likelihood, and it substantially outperforms 
them when assessing the risk of familial predisposition 
to breast or ovarian cancer.10
Analysis
To assess the relation between factors covered by the ques-
tionnaire and the strengths of having a familial predis-
position for ovarian cancer according to the Manchester 
scoring system, patients were divided into two groups: 
those with a 10% or higher likelihood of having a famil-
ial predisposition and those with a lower than 10% like-
lihood. For this analysis, logistic regression was applied 
in order to obtain the odds ratio (OR) and 95% confidence 
interval (95% CI). All tests were two sided and p<0.05 was 
considered statistically significant.
results
The questionnaire was administered to 59 patients from 
our outpatient clinic. Of this total, 51 patients with in-
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vasive carcinomas were included (Table 1): 42 serous ad-
enocarcinomas, 6 endometrioid adenocarcinomas, 1 muci-
nous adenocarcinoma, 1 mixed mullerian adenocarcinoma 
and 1 borderline tumor with invasive areas. Eight patients 
were excluded: a borderline tumor (1), a benign lesion (1), 
metastasis from other primary sites (2), recurrence of a 
tumor diagnosed before 2009 (4).
TABLE 1 Patients’ characteristics.
Age (current) – median (min-max) 57 (36 - 76)
BMI – median (min-max) 27.9 (17.8 - 39.7)
Menarche (age) – median (min-max) 13.0 (9 - 17)
Menopause (age) – median (min-max) 48.0 (35 - 60)
Use of oral contraceptives (months) – median 
(min-max)
12 (0-144)
Full term pregnancies – median (min-max) 2 (0 - 15)
Breast feeding (months) – median (min-max) 2 (0 - 168)












Of the 51 patients included in the analysis, 32 reported 
previous oral contraceptive use and 11 informed no pre-
vious pregnancies (Table 1). Only five of these patients 
had not been submitted to an oophorectomy until the 
moment of the interview. Four patients had been previ-
ously diagnosed with other primary tumors besides ovar-
ian cancer: three had breast cancer and one had endome-
trial cancer.
Regarding family history, ten patients reported hav-
ing at least one first-degree relative with breast or ovari-
an cancer. When we included also second-degree relatives 
in the pedigree chart, the number increased to seventeen. 
Three of the patients interviewed had no contact with 
their families and had no information about their rela-
tives’ causes of death. From all patients included in this 
study, 11 were diagnosed with ovarian cancer before age 
50 years, while 40 were fifty or older at the diagnosis. When 
calculating the likelihood of familial predisposition for 
cancer, 12 patients had a higher than 10% risk of having 
a familial predisposition for the disease, while in 39 pa-
tients this risk was lower than 10% (Table 2).
From all variables covered by the questionnaire, hav-
ing comorbidities was more frequent among patients 
with a likelihood of familial predisposition lower than 
10% compared to patients in which this likelihood was 
10% or higher (69.2 vs. 33.3%, OR: 0.22, 95% CI: 0.06-0.88) 
(Table 3).
discussion
In this study, we assessed the relation between clinical 
and demographic characteristics of patients diagnosed 
with ovarian cancer and having an increased risk for a fa-
milial predisposition to ovarian cancer, based on person-
al and family history of cancer. We observed a significant-
ly higher frequency of comorbidities among women with 
a lower than 10% chance of having a familial predisposi-
tion for ovarian cancer. All other factors evaluated by this 
study did not present a significant correlation with the 
risk of having such genetic predisposition.
There are very few studies in the literature addressing 
the correlation between clinical characteristics of breast and 
ovarian cancer patients and their likelihood of harboring 
BRCA1/2 mutation, all of them in breast cancer patients/
family members. Our findings are in line with previous stud-
ies addressing this topic.11-13 Atchley et al. evaluated clini-
cal and pathological characteristics of patients with BRCA-
positive and -negative breast cancer and found that well 
established risk factors did not differ between women with 
or without BRCA mutations and that ethnic background 
was similar among mutation carriers and noncarriers.11 Lat-
er on, in a multivariate logistic model, Bayraktar et al. eval-
uated women with ductal carcinoma in situ, finding that a 
family history of at least 2 family members with ovarian 
cancer was significantly associated with a higher rate of 
BRCA positivity regardless of age at diagnosis (OR 8,81).12 
Previously, in a study that aimed at finding associations be-
tween clinical characteristics and positive mutation status 
in Finnish breast cancer families, Vahteristo et al had also 
observed that the number of ovarian cancer cases in a fam-
ily, as well as the age of the youngest breast cancer case were 
independent predictors of BRCA mutations.13
TABLE 2 patients risk factors for ovarian cancer.
Family history N
No breast or ovarian cancer in 1st degree relatives 39
Breast or ovarian cancer cases in 1st degree relatives 10
Age at diagnosis of ovarian cancer
Before age 50 11
At age 50 or older 40
Risk of mutation detection according to Manchester 
score
Lower than 10% 39
10% or higher 12
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ing a familial predisposition for ovarian cancer. In order 
to access the likelihood of having such familial predispo-
sition in our patients, we used the Manchester scoring 
system,10 which is based on the patient’s personal and 
family history of cancer to predict the risk of finding 
BRCA1 or BRCA2 mutations. There are several studies 
aiming at predicting the probability of a genetic predis-
position to breast and ovarian cancer in individuals or 
families.17-19 These studies resulted in the development 
of advanced computer prediction models that rely most-
ly on family history of breast and ovarian cancer, tumor 
characteristics and age at diagnosis. The Manchester scor-
ing system is simpler than the aforementioned comput-
er mutation prediction model. The main reason for choos-
ing such scoring system was that information on family 
history is often incomplete and not always accurate, mak-
ing it difficult to fill in the information required by these 
models correctly, which could lead to unreliable results. 
DNA analysis on blood samples would provide more ac-
curate information on genetic predisposition for cancer 
Regarding age at cancer diagnosis, previously pub-
lished studies show contradictory results. There are stud-
ies reporting a higher rate of mutation detection in wom-
en diagnosed with breast cancer at younger age14 and 
others that show similar mutation rates among younger 
and older patients.12,15,16 In this study we found no corre-
lation between age at diagnosis of ovarian cancer and 
probability of familial predisposition for cancer.
Furthermore, there are studies aiming at identifying 
tissue-based predictors of mutations in patients with 
breast cancer. De la Cruz et al. found that estrogen recep-
tor positive phenotype was inversely associated with the 
presence of BRCA1 mutation (OR 0.24) and that high mi-
totic activity was directly associated with BRCA1 muta-
tion (OR 4.22).6 In our study, we found no evidence of as-
sociation between tumor type and risk of mutation 
detection. We did not access other pathological charac-
teristics of the tumors.
The main outcome in this study was the association 
of clinical and demographic factors with the risk of hav-
TABLE 3 Patients’ characteristics compared to likelihood of BRCA1/2 mutation detection.
Variable Likelihood of BRCA1/2 mutation detection
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and would be the preferred method on such analysis. How-
ever, since DNA analysis is not yet available through the 
Brazilian public healthcare system, this scoring system is 
the second best option.
Our results must be interpreted in light of the limi-
tations of this study. Our main limitations are the small 
number of patients enrolled and their difficulties to re-
call family history. In Brazil, especially for older genera-
tions, many deaths are left undiagnosed. There are many 
individuals who migrated to/from different areas of the 
country and have little contact with their relatives. These 
facts probably lead to a considerable amount of missing 
relatives in the pedigrees, which maybe could lead us to 
underestimate the risk of familial predisposition to can-
cer. It is also important to take into account that the mod-
el we applied is not validated in this population and it is 
not completely sensitive and specific for the presence of 
a mutation, hence genetic testing should be performed 
in the future for more accurate information. Since we 
have no DNA analysis, it was not possible to study the 
impact of the factors evaluated by this study on the rates 
of mutation detection, which would be very enriching in 
this analysis. The strong points of our study are that all 
patients included were followed at the same hospital and 
pathology reports from all patients were available, as well 
as the fact that all patients were interviewed by the same 
person.
conclusion
In this study, we found that having comorbidities is as-
sociated with a lower risk of having familial predisposi-
tion for cancer. Other factors associated with the risk of 
ovarian cancer did not have an impact on the likelihood 
of heredity of the cancer. Considering that currently avail-
able screening strategies are not effective6-7 and that risk 
reducing salpingo-oophorectomy (RRSO) significantly 
lowers ovarian cancer risks8-9 by detecting women with a 
higher risk of developing ovarian cancer, providing them 
counseling over risk reduction measures is essential for 
preventing this disease in this group of high risk women. 
Since the currently available prediction models are not 
very specific and sensitive, and not so widely available for 
clinicians, further studies are needed to evaluate other 
factors associated with ovarian cancer that might be as-
sociated with the probability of familial cancer.
resuMo
Associação de história familiar e estilo de vida a comor-
bidades em pacientes com câncer de ovário.
Objetivos: analisar fatores que possam indicar uma pre-
disposição familiar ao câncer de ovário em pacientes com 
este diagnóstico. 
Métodos: em estudo de coorte prospectiva realizado no 
Instituto do Câncer do Estado de São Paulo (ICESP), fo-
ram incluídas 51 mulheres diagnosticadas com câncer de 
ovário entre janeiro de 2009 e dezembro de 2011. Predis-
posição familiar para câncer de ovário foi definida como 
um risco maior de 10% de apresentar uma mutação em 
BRCA1/2, de acordo com o sistema de pontes de Man-
chester, um método validado para avaliar a probabilida-
de de detecção de mutação nesses genes. Cada paciente 
foi entrevistada com um questionário padronizado, abor-
dando fatores de risco para câncer de ovário e outros fa-
tores que pudessem influenciar o risco de desenvolver a 
doença. O impacto dos fatores avaliados na probabilida-
de de detecção da mutação foi avaliado com regressões 
logísticas. 
Resultados: dezessete das 51 pacientes referiram histó-
ria familiar de câncer de mama e/ou ovário, quatro pa-
cientes apresentavam antecedente pessoal de câncer de 
mama ou endométrio, 11 haviam sido diagnosticadas an-
tes dos 50 anos e 12 apresentaram um risco maior que 
10% de predisposição familiar a câncer de ovário. Pacien-
tes com comorbidades como hipertensão, diabetes, dis-
funções hormonais, dislipidemia e distúrbios psiquiátri-
cos apresentaram menor risco de predisposição familiar 
ao câncer de ovário (OR: 0.22; IC 95%: 0.06-0.88; p=0.03). 
Conclusão: neste estudo, apresentar alguma comorbida-
de foi associado a um menor risco de ter uma predispo-
sição familiar ao câncer de ovário. Outros fatores asso-
ciados ao risco de câncer de ovário não tiveram nenhum 
impacto sobre esta predisposição.
Palavras-chave: neoplasias ovarianas, fatores de risco, 
síndromes neoplásicas hereditárias.
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